Daily Sepsis Research Analysis
Three sepsis studies stood out today: a massive machine learning study developed and externally validated a non-laboratory ED screening tool (qSepsis) that outperformed SIRS, qSOFA, and MEWS; a mechanistic study uncovered Shh/Gli1-driven Dio3 reactivation as a driver of muscle metabolic dysfunction in sepsis; and a pre-registered statistical analysis plan for the ANDROMEDA-SHOCK-2 RCT sets a transparent, hierarchical win-ratio approach for phenotype-based, capillary refill time-targeted resuscit
Summary
Three sepsis studies stood out today: a massive machine learning study developed and externally validated a non-laboratory ED screening tool (qSepsis) that outperformed SIRS, qSOFA, and MEWS; a mechanistic study uncovered Shh/Gli1-driven Dio3 reactivation as a driver of muscle metabolic dysfunction in sepsis; and a pre-registered statistical analysis plan for the ANDROMEDA-SHOCK-2 RCT sets a transparent, hierarchical win-ratio approach for phenotype-based, capillary refill time-targeted resuscitation.
Research Themes
- AI-enabled, non-laboratory sepsis screening in the ED
- Thyroid hormone inactivation (Dio3) and Shh/Gli1 signaling in sepsis muscle metabolism
- Transparent trial methodology for phenotype-guided, capillary refill time-targeted resuscitation
Selected Articles
1. Development and validation of a screening tool for sepsis without laboratory results in the emergency department: a machine learning study.
Using non-laboratory ED data, the qSepsis machine-learning model (logistic regression) achieved AUROC 0.862 internally and 0.766 in external validation, outperforming SIRS, qSOFA, and MEWS. Precision-recall analysis (AUPRC 0.213) indicates better case finding than comparators but with low PPV that may increase false alarms in practice.
Impact: Demonstrates scalable, lab-free sepsis screening that generalizes across continents and outperforms widely used bedside scores, addressing a critical time bottleneck in the ED.
Clinical Implications: qSepsis can aid rapid triage when labs are delayed or unavailable, especially in prehospital or high-throughput ED settings. It should augment, not replace, clinician judgment, and be paired with confirmatory testing due to low PPV; prospective implementation studies are needed.
Key Findings
- Logistic regression qSepsis achieved AUROC 0.862 (95% CI 0.855–0.869) internally and 0.766 (0.758–0.774) externally.
- qSepsis outperformed SIRS (AUROC 0.704), qSOFA (0.579), and MEWS (0.600) in external validation.
- AUPRC was 0.213 for qSepsis versus 0.071 (SIRS), 0.096 (qSOFA), and 0.083 (MEWS), but with low PPV indicating potential false alarms.
Methodological Strengths
- Extremely large derivation cohort (n=414,864) and external validation (n=200,089) across countries
- Direct benchmarking against SIRS, qSOFA, and MEWS; multiple ML algorithms compared
Limitations
- Retrospective design with potential labeling bias tied to Sepsis-3 definitions
- Low PPV may increase false alarms; no prospective impact or clinical workflow evaluation
Future Directions: Prospective, multi-site implementation trials to assess clinical impact, alarm burden, and equity; model calibration across diverse EDs; integration with prehospital triage systems.
BACKGROUND: Sepsis is a significant health burden on a global scale. Timely identification and treatment of sepsis can greatly improve patient outcomes, including survival rates. However, time-consuming laboratory results are often needed for screening sepsis. We aimed to develop a quick sepsis screening tool (qSepsis) based on patients' non-laboratory clinical data at the emergency department (ED) using machine learning (ML), and compare its performance with established clinical scores. METHODS: This retrosp
2. Type 3 deiodinase activation mediated by the Shh/Gli1 axis promotes sepsis-induced metabolic dysregulation in skeletal muscles.
In septic rats and human tissues, Dio3 was upregulated early, with rT3 associating with organ dysfunction. Skeletal-muscle–targeted Dio3 inhibition restored thyroid hormone responsiveness, preserved GLUT4 function and muscle mass, and maintained protein turnover balance. Dio3 reactivation was transcriptionally driven by Shh/Gli1 induced by STAT3, and Shh inhibition improved systemic TH actions.
Impact: Reveals a previously underappreciated mechanism linking Shh/Gli1 signaling to tissue thyroid hormone inactivation and sepsis-associated muscle wasting, highlighting Dio3/Shh as therapeutic targets.
Clinical Implications: While preclinical, targeting Dio3 or upstream Shh/Gli1 signaling could mitigate septic muscle catabolism and anabolic resistance; biomarker-guided approaches using rT3 may stratify patients for future trials.
Key Findings
- Early sepsis upregulated Dio3 in skeletal muscle and lung, with rT3 strongly associated with organ function.
- Muscle-targeted Dio3 inhibition restored tissue TH actions, preserved GLUT4 function, prevented fast-to-slow fiber shift, and maintained protein synthesis–proteolysis balance, preserving muscle mass.
- Dio3 reactivation was transcriptionally driven by Shh/Gli1 induced by STAT3; Shh inhibition (cyclopamine) improved systemic TH responsiveness.
Methodological Strengths
- Multi-system approach with CLP rat model and human biopsy samples
- Mechanistic validation via RNA-seq and ChIP-qPCR alongside functional metabolic readouts
Limitations
- Preclinical study; translational applicability and safety of Dio3/Shh targeting remain untested in humans
- Human tissue sampling details and sample sizes are not specified in the abstract
Future Directions: Phase 0/1 studies to assess target engagement and safety of Dio3/Shh modulation; exploration of rT3 as a stratification biomarker; integration with nutrition and rehabilitation strategies in sepsis.
BACKGROUND: Non-thyroidal illness syndrome is commonly observed in critically ill patients, characterized by the inactivation of systemic thyroid hormones (TH), which aggravates metabolic dysfunction. Recent evidence indicates that enhanced TH inactivation is mediated by the reactivation of type 3 deiodinase (Dio3) at the tissue level, culminating in a perturbed local metabolic equilibrium. This study assessed whether targeted inhibition of Dio3 can maintain tissue metabolic homeostasis under se
3. Statistical analysis plan for hemodynamic phenotype-based, capillary refill time-targeted resuscitation in early septic shock: the ANDROMEDA-SHOCK-2 randomized clinical trial.
This pre-registered SAP for a multicenter RCT specifies a hierarchical primary endpoint analyzed via stratified win ratio, with detailed subgroup and sensitivity analyses for capillary refill time-targeted, phenotype-based resuscitation versus standard care in early septic shock. Publishing the SAP before database lock aims to minimize analysis bias and enhance transparency.
Impact: Sets a rigorous, transparent analytic framework (stratified win ratio) for a pivotal resuscitation RCT, enabling credible evaluation of a phenotype-guided, CRT-targeted strategy likely to influence practice if effective.
Clinical Implications: While outcomes are pending, the SAP increases confidence that trial results will be interpretable and less prone to bias; if positive, CRT-targeted, phenotype-based resuscitation may be adopted and studied in implementation.
Key Findings
- Hierarchical primary outcome will be analyzed using a stratified win ratio to compare CRT-targeted, phenotype-based resuscitation versus standard care.
- Prespecified secondary/tertiary outcomes, subgroup analyses, and sensitivity analyses are detailed to minimize analytic flexibility.
- Comprehensive presentation plan includes mock tables, baseline characteristics, and treatment effect reporting prior to database lock.
Methodological Strengths
- Pre-registered statistical analysis plan with hierarchical win ratio for clinically meaningful composite assessment
- International, multicenter RCT design with prespecified subgroup and sensitivity analyses
Limitations
- No clinical outcomes reported yet; impact depends on forthcoming trial results
- Sample size and operational nuances not detailed in the abstract
Future Directions: Execute the RCT per SAP, then assess generalizability and implementation of CRT-targeted, phenotype-based resuscitation; consider patient-centered outcomes within a hierarchical framework.
BACKGROUND: ANDROMEDA-SHOCK 2 is an international, multicenter, randomized controlled trial comparing hemodynamic phenotype-based, capillary refill time-targeted resuscitation in early septic shock to standard care resuscitation to test the hypothesis that the former is associated with lower morbidity and mortality in terms of hierarchal analysis of outcomes. OBJECTIVE: To report the statistical plan for the ANDROMEDA--SHOCK 2 randomized clinical trial. METHODS: We briefly describe the trial desig